Over the past decade, molecular targeted therapies have been applied in the treatment of advanced HCC; however, the multikinase vascular endothelial growth factor receptor (VEGFR) inhibitors, including sorafenib and lenvatinib or anti-VEGF/VEGFR monoclonal antibodies, showed limited efficacy and common toxicities [6]. The gene discussed is KDR; the disease is hepatocellular carcinoma.